Novartis Ag

Astex Therapeutics Limited

Dana-farber-cancer Institute Inc.

The Broad Institute, Inc.

Array Biopharma Inc.

Sunkyu Kim

Shivang Doshi

Yan Chen

Giordano Caponigro

Scott Delach

Kristy Haas

Steven Kovats

Alan Xizhong Huang

Miles Stuart Congreve

Michael Luzzio

Steven Howard

Gianni Chessari

Alison Jo-Anne Woolford

Bharat Lagu

Lawrence Blas Perez

Andrew James Woodhead

Fan Yang

Christine Hiu-Tung Chen

Christopher Thomas Brain

Levi A Garraway

Darrin Stuart

Young Shin Cho

Yaping Wang

Xizhong Huang

John William Giraldes

Claudio Dagostin

Marc O'Reilly

Yipin Lu

Steven Douglas Hiscock

Thomas Horn-Spirohn

Paul Mortenson

Zainab Jagani

Alice Loo

Jianguo Ma

Maria Borland

Michael Joseph Luzzio

Gregory Kryukov

Hong Zhang

Josh Murtie

Paul Neil Mortenson

John Grialdes

A combination of a CDK4/6 inhibitor and a P3Kinase inhibitor for the treatment of cancer.

Combination therapy comprising a CDK4/6 inhibitor and a PI3K inhibitor for use in the treatment of cancer

A combination of a CDK4/6 inhibitor and a MEK inhibitor for the treatment of diseases such as cancer.

Pharmaceutical combination comprising binimetinib

A pharmaceutical combination comprising (a) CDK4/6 inhibitor (b) a B-Raf inhibitor, and optionally (c) a MEK 1/2 inhibitor; combined preparations and pharmaceutical compositions thereof; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.

Pharmaceutical combinations of a CDK4/6 inhibitor and a B-RAF inhibitor

The present invention relates to a pharmaceutical combination comprising (1) a first agent which is a CDK inhibitor or a pharmaceutically acceptable salt thereof and (2) a second agent which is a mTOR inhibitor or a pharmaceutically acceptable salt thereof.

Combination therapy

Combination therapy comprising a CDK4/6 inhibitor and a P13K inhibitor for use in the treatment of cancer

The invention provides compounds of the formula (I): and salts, tautomers, solvates and N-oxides thereof;wherein Q is CH or N; X is N, N&#x2014;Oor CR; Y is N, N&#x2014;Oor CR; Rand Rare independently selected from hydrogen and various substituents as defined in the claims; or Rand Rtogether with the atoms to which they are attached, link to form an optionally substituted carbocyclic or heterocyclic aromatic or non-aromatic ring of 4 to 7 members; Ris selected from hydrogen and various substituents; and Ris selected from hydrogen and various substituents as defined in the claims. Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds. The compounds of formula (I) have activity as inhibitors of CDK kinases and are useful in the treatment of inter alia proliferative diseases such as cancers.

Imidazole derivatives and their use as modulators of cyclin dependent kinases

Growing community of inventors

Cambridge, MA, United States of America

Sunkyu Kim